Subclinical Hyperthyroidism and the Cardiovascular Disease

Author
Alessandro P. Delitala

Affiliation
Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy

Key words
thyroid disorders, cardiovascular disease, atrial fibrillation, heart failure, stroke, mortality

received 18.05.2017
accepted 28.07.2017

Bibliography
DOI https://doi.org/10.1055/s-0043-117893
Published online: 15.9.2017
Horm Metab Res 2017; 49: 723–731
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0018-5043

Correspondence
Dr. Alessandro P. Delitala
Azienda Ospedaliero-Universitaria di Sassari
Clinica Medica
Viale San Pietro 8
07100 Sassari

ABSTRACT
Thyroid hormone excess has complex metabolic effects, particularly on the cardiovascular system. Treatment of these conditions is universally suggested by international guidelines. Subclinical hyperthyroidism, defined by reduced or suppressed TSH levels in the presence of normal free thyroxine and free triiodothyronine values, is common in the general population and progressively increases with aging, being as high as 15.4 % in subjects more than 75 years old and more frequent in subjects with nodular goiter. Subclinical hyperthyroidism is often asymptomatic and the diagnosis is incidentally made during screening exams. However, this form of thyroid disorder has gained attention in the last years for its association with cardiovascular disease, in particular with atrial fibrillation. Less clear are the effects of subclinical hyperthyroidism on blood pressure, stroke, or heart failure. The decision to treat subclinical hyperthyroidism is made on the clinical judge, particularly in elderly patients and/or in the presence of comorbidities.

Introduction
Hormones and cardiovascular system are strongly associated and disorders of hormonal secretion may lead to increased cardiovascular risk [1, 2]. Thyroid hormones exert important actions on the cardiovascular system, as demonstrated by the adverse clinical effects that can occur in states of hyperthyroidism and hypothyroidism. Patients with hyperthyroidism have alterations in cardiovascular function, which is in part due to the hypermetabolism and the need to dissipate the excess of heat produced [3]. Thyroid disorders can impair the cardiovascular risk factors, such as those included in the definition of metabolic syndrome [4, 5]. Indeed, excess as well as lack of thyroid hormone have been linked to alteration in the cardiovascular hemodynamic [6], modifications of heart rhythm [7, 8] and arterial wall structure [9–11]. While the effects of thyroid hormone excess on the cardiovascular risk factors are clear for some of them, others are still debatable [12, 13]. Finally, a worst lipid profile has been demonstrated in hypothyroidism [14, 15], while a hyperthyroid state was associated with an accelerated lipid metabolism and increased frequency of hepatic injury [16, 17].

Overt thyroid disorders, defined as an alteration of thyrotropin (TSH) with increased free thyroxine (FT4) and/or free triiodothyronine (FT3) are clinically evident and an early diagnosis is usually made. Treatment is universally suggested by guidelines for a prompt relief of symptoms and to avoid long-term consequences. Subclinical disorders of thyroid gland, defined as TSH outside the reference range of values and FT3 and FT4 within the normal range, are more subtle diseases and the diagnosis is incidentally made during screening exams. Subclinical hyperthyroidism, defined as low TSH and free hormones within the reference range, has gained attention in the last years for its association with cardiovascular disease (CVD), in particular with atrial fibrillation (AF). Aging is associated with a deterioration of classical cardiovascular risk factors but, albeit subclinical hyperthyroidism is more prevalent in the elderly, the temporality ascertainment between thyroid dysfunction and onset of CVD is not always estimable. Further, there is lack of randomized prospective controlled studies conceived to assess the treatment of the disorder, which, in addition, is limited by a variety of side effects. Treatment of subclinical hyperthyroidism is similar to the therapy of overt hyperthyroidism [19, 20], but the indication for the treatment has not been standardized.

Here, we have reviewed the effect of subclinical hyperthyroidism on CVD and mortality.
Delitala AP. Subclinical Hyperthyroidism and the Cardiovascular System: Horm Metab Res 2017; 49: 723–731

Materials and Methods
We performed on PubMed a literature search for the articles published until March 2017 by using the search terms ‘subclinical hyperthyroidism’, ‘cardiovascular disease’, ‘atrial fibrillation’, ‘blood pressure’, ‘stroke’, ‘heart failure’, ‘all-cause mortality’. Titles of interest were further reviewed by abstract.

Epidemiology
Subclinical hyperthyroidism is common in the general population and its frequency is variable, depending on age, sex, and iodine status. In the National Health and Nutrition Examination Survey, 2.5% of the population had serum TSH below the lower limit of reference range [21]. In Europe, some population surveys analyzed the prevalence of thyroid disorders with different results, perhaps reflecting different age ranges of cohorts and other environmental factors. In Italy the prevalence of subclinical hyperthyroidism not previously diagnosed was 2.4% [22], while in Germany Volzke et al. found a prevalence of 1.8% [23]. Another survey in Italy found an overall prevalence of thyroid functional autonomy (i.e., subnormal TSH concentrations and normal concentration of FT3 and FT4) of 4.6%. Finally, the overall prevalence of subclinical hyperthyroidism was lower in Spain (1.3%) [24] and higher in Denmark (9.7%) [25].

The frequency of subclinical hyperthyroidism progressively increases with aging, being as high as 15.4% in subjects more than 75 years old and was more frequent in subjects with nodular goiter [26]. Further, the prevalence of functional thyroid autonomy is much higher than that reported in iodine-sufficient areas, where this condition is rare. Non-autoimmune hyperthyroidism is usually found in subjects with long-standing nodular goiter and is increased in iodine deficient area due to an increased frequency of toxic nodular goiter [26], and consequently, subclinical hyperthyroidism is more frequent in iodine deficient in comparison compared to an iodine replete area [24, 27, 28].

Progression to overt hyperthyroidism
The evolution of subclinical hyperthyroidism is variable. Some subjects may progress to overt hyperthyroidism, or can revert to euthyroidism. In general, subclinical hyperthyroidism tends to be stable over years in subjects with multinodular goiter in area with iodine deficiency. However, the risk of progression to toxic multinodular goiter is higher in area with adequate iodine intake and occurred in 10% of subjects after 5 years of follow-up [29].

Level of TSH is a strong predictor of progression to overt hyperthyroidism (suppressed TSH, FT3, and FT4 over the upper limit of reference range). After 7 years of follow-up, subjects with mild reduction of TSH (TSH 0.4–0.1) have a low risk to progression (less than 1%) [30], while 20% of patients with decreased TSH level (0.1 mUI/ml or lower) progress to overt hyperthyroidism [31]. Subclinical hyperthyroidism may be also transient and may normalize in 25–50% of subjects particularly in autoimmune-mediated hyperfunction of the gland [32, 33].

Thus, the natural history of subclinical hyperthyroidism is unpredictable but it can be precipitated by iodine overload (drugs or contrast agent for computed tomography), which favors the progression to overt hyperthyroidism.

Thyroid hormone and the cardiovascular system
Thyroxine (T4) is the most abundant hormone secreted by the thyroid gland and is converted into triiodothyronine (T3), the biologically active compound, by type 1 iodothyronine deiodinases (ID), which is distributed widely and maintains circulating T3 levels. Type 2 ID catalyze the inactivation of FT4 and FT3 while type 3 ID acts like type 1 ID, and is expressed in skeletal and cardiac muscles, and in vascular smooth muscle, thus providing local intracellular production of T3 [34].

The effects of thyroid hormones on the cardiovascular system are complex and multiple [35], and include genomic and non-genomic effects. In the heart, once the conversion from T4 to T3 is performed, which usually occurs outside cardiac myocytes [34], T3 enters inside the nucleus of the myocytes, binds and activates nuclear receptors that mediates changes in gene expression, which encode the production of structural and regulatory proteins. Thus, T3 has a positive chronotropic and inotropic effect on systolic function and further increases the speed of diastolic relaxation [36]. These effects are mediated through the binding of T3 with thyroid hormone receptor (TR). TR is widely expressed and exists in two forms: TR-α, encodes by TR-α gene (chromosome 19), and TR-β, which is derived from TR-β gene (chromosome 3) [37]. Both TR occurs in different isoforms with a specific tissue expression: TR-α1 is a functional receptor that binds triiodothyronine (T3) and is highly expressed in cardiac and skeletal muscles; TR-α2 is a non-hormone binding receptor acting as negative regulator. Isoforms of TR-β are generated by alternative promoter choice: TR-β1 is predominately expressed in liver and is involved in cholesterol and bile acid metabolism and TR-β2 [15], which is primarily limited to the hypothalamus and pituitary where it plays a key role in negative feedback of thyroid hormone on the thyroid hypothalamic axis [38–40]. The number of β-adrenergic receptor are also increased in cardiac myocytes and pulse rate frequency are the result of thyroid hormone action on these receptors [3]. Additional actions of thyroid hormone on the heart include adenyl cyclase activity, calcium transport, sodium-potassium ATPase, and cardiac myosin ATPase isoenzymes [41]. In particular, thyroid hormone excels favors the production of α-chain, which results in increased ATP to ADP conversion thus enhancing myocardial contractility. β-Chains have reduced capacity to convert ATP to ADP resulting in weak cardiac contractility. The expression of messenger RNA that encodes these chains is lower in hyperthyroidism whereas messenger RNA that encodes the alpha-chains is high. These differences are mediated, but the different effects of thyroid hormone excess on the expression of the genes are due to heavy chains [41].

The non-genomic effects of the thyroid hormones have a more rapid onset of action and include changes in performance of calcium, sodium and potassium channel at heart level [42]. Moreover, thyroid hormones interact with the sympathetic nervous system by altering responsiveness to sympatho-stimulation probably by modulating adrenergic receptor action and/or density. Pathophysiological consequences of such direct and indirect thyroid hormones effects include increased myocardial contractility and relaxation.

In addition, thyroid hormones exert effects on the vascular system, since they decrease systemic vascular resistance by vasodilatation of the peripheral circulation. This effect is possibly mediated by a direct action on vascular smooth muscle cells or through stim-
ulation of vasodilatory endothelium-derived substances such as nitr
ic oxide. Peripheral vascular resistance is therefore decreased
whereas cardiac output is increased due to an increase in heart rate
and stroke volume. Another mechanism might be the interaction
of thyroid hormone with the sympathetic nervous system.

Many of the clinical manifestations of hyperthyroidism are simi-
lar to those of sympathetic system activation. However, plasma
and urine concentrations of catecholamines are not increased in
patients with hyperthyroidism. Therefore, thyroid hormones may
increase sensitivity to catecholamines in heart and other tissues.

Atrial fibrillation

Atrial fibrillation is a well-known complication of overt hyper-
thyroidism, and has been found in 2–30% at the time of diagnosis
of overt hyperthyroidism [43, 44]. Although only a low percentage
of subjects with AF has a functional disorder of the thyroid gland [45],
European Society of Cardiology suggests to evaluate thyroid func-
tion in all patient with a recent diagnosis of AF [46]. Following stud-
ies demonstrated that also subclinical hyperthyroidism is a risk fac-
tor for AF. In a study on older subjects during the period of 2007,
Sawin et al. showed that 28% of patients with subclinical hyperthy-
roidism developed AF as compared to 11% of those with normal
thyroid function. Further, patients with low TSH concentration have
a relative risk three time higher to develop AF in comparison to eu-
thyroid subjects. Although even patients with subclinical hypo-
thyroidism (defined as increased serum TSH value with normal FT4 and
FT3) developed AF, their 10-years incidence was comparable to that
of euthyroid subjects [47], as shown in ▶ Table 1. Similar results
have been obtained by Auer et al. in a cross sectional study, which
analyzed > 23 000 patients aged 45 or older who were referred to
a single center [48]. They found an increased prevalence of AF in
subjects with overt and subclinical hyperthyroidism (13% and 14%,
respectively) in comparison to euthyroid subjects (2%). Notably,
other authors found that serum FT4 levels was a predictor on AF, as
in subclinical hyperthyroidism, as in subjects with normal thy-
roid function [49]. Similar results have been obtained by Heeringa
et al. in a population-based survey in Holland [50]. They analyzed
1426 elderly subjects (>65 years) with normal thyroid function for
a median follow-up of 8 years. Subjects in the lowest quartile of
TSH within the reference range have 2-fold increased risk of AF in
comparison to those in the highest quartile. Further, FT4 showed
a graded association with AF, increasing from the second quartile
to the highest quartile of FT4. Increased risk of AF was reported in
subjects with suppressed TSH [51] and in those with TSH < 0.1 mU/l
and underlying cardiac disease [48].

Subclinical hyperthyroidism, both endogenous and exogenous,
might predispose to other cardiac arrhythmias, such as atrial pre-
mature and ventricular premature beats [52, 53], which decreased
after reaching euthyroidism [52].

Predictors of paroxysmal AF, such as specific EKG parameter,
and their relation with subclinical hyperthyroidism have been investigat-
ed in some studies [54–56]. Duration of P wave duration and P wave
dispersion were higher in subjects with subclinical hyperthyroidism
as compared to healthy euthyroid group. Intriguingly, the etiology
of subclinical hyperthyroidism did not modify the association with
EKG parameters, suggesting that alteration of hormone levels rath-
er than its cause might be link with cardiac arrhythmias [54].

The effect of exogenous subclinical hyperthyroidism and AF in
subjects with thyroid cancer has not yet been extensively studied.
Some authors described an increased heart rate frequency, which
decreased during withdrawl of thyroxine [57, 58] with a higher preva-
lence of premature atrial beats at ambulatory electrocardio-
graphic monitoring [58].

Despite nearly all studies describe this association, other authors
found that mild subclinical hyperthyroidism was not associated
with higher prevalence of AF in elderly women [59]. Treatment of
subclinical hyperthyroidism was associated with spontaneous con-
version to sinus rhythm in 19% of the patients, which had also a
lower frequency of underlying heart disease in comparison to non-converter (77% vs. 36%) [48].

Taken together these data strongly suggest an association be-
tween AF and subclinical hyperthyroidism in particular in elderly
patients. Indeed, these patients may have a longer duration of sub-
clinical hyperthyroidism, which is often asymptomatic, and often
have pre-existing heart disease such as heart failure, angina, and
hypertension, which are all independent risks factors for the onset
of AF. Another possibility is that hyperthyroidism might shorten
the duration of the repolarization phase of the action potential,
thus favoring the probability of arrhythmias [60]. The most prob-
able hypothesis is that subclinical hyperthyroidism might trigger
the onset of AF in genetically predisposed subjects with other cardio-
vascular risk factors.

Blood pressure

Hypertension is the most common cardiovascular risk factor and
may affect over than 30–45% of the population [61], with an in-
creased frequency during aging [18]. The risk of hypertension in
overt hyperthyroidism is well documented but the effect of sub-
clinical hyperthyroidism is debatable. In Busselton Thyroid Study,
subjects with reduced TSH concentration (< 0.4 mU/l) had an in-
creased frequency of hypertension and an increased mean systolic
blood pressure, although the latter was restricted to subjects with
serum TSH concentrations of < 0.1 mU/l [62]. However, the study,
as acknowledged by the authors, was limited by the low sample
(n = 35). A recent study recorded 24-h ambulatory blood pressure
monitoring in 44 normotensive subjects with endogenous subclin-
ical hyperthyroidism [63]. The study showed that patients with sub-
clinical hyperthyroidism had a higher nocturnal mean systolic blood
pressure, mean diastolic blood pressure, blood pressure load, and
mean arterial pressure in comparison to euthyroid state. However,
in a German population survey, subclinical hypertension was not
associated with hypertension [64]. Although subjects with subclin-
ical hyperthyroidism had increased systolic blood pressure, as com-
pared to euthyroid, adjusting for confounders revealed lower rath-
er than higher adjusted mean values for systolic blood pressure.
The same authors followed longitudinally the patients with sub-
clinical hyperthyroidism and they found that it was not associated
with changes in blood pressure, pulse pressure, or incident hyper-
tension [65]. The 5-year hypertension incidence was higher in those
with subclinical hyperthyroidism as compared to those with TSH
within the reference range in the univariate analysis (31% vs. 19%).
Logistic regression adjusted for cardiovascular confounders re-
vealed that both groups had similar risk of hypertension. Further,
two recent case-control studies, aimed to investigate the associa-
tion between morphological cardiac parameters [66], and electrocardiogram and echocardiographic characteristics [67], showed that patients with subclinical hyperthyroidism had similar systolic and diastolic blood pressures as euthyroid controls.

Data of the effect of exogenous subclinical hyperthyroidism are rather scanty. Casu et al. showed that patients receiving suppressive l-thyroxine therapy for thyroid cancer had an increased systolic and mean blood pressure, as in ortostatism and in clinostatism [68]. The data, taken together, seems to suggest a small effect of subclinical hyperthyroidism on blood pressure, which can be defined statistically significant but clinically insignificant [63].

**Stroke**

Ischemic stroke recognizes two most common causes: thrombotic stroke and embolic stroke. The latter is typical in subjects with AF while thrombotic stroke is associated with atherosclerosis. The risk of stroke in patients with subclinical hyperthyroidism could be related by the increased frequency of AF, but also by the alterations of coagulation parameters found in subclinical hyperthyroidism [69]. The frequency of unknown thyroid dysfunctions can be found in 12 % in patients with acute ischemic stroke [70]. However, results of clinical studies and systematic reviews gave conflicting results. In 3233 subjects from Cardiovascular Health Study, the incidence of cerebrovascular event was not increased [71]. These data were confirmed in analysis that included 52 674 subjects from 10 cohort studies [72]. Further, acute stroke was not associated with subclinical hyperthyroidism also in specific population highly predisposed to cardiovascular event, such as diabetic hemodialysis patients [73]. Conversely, Schultz et al. found an increased incidence of stroke in subjects with subclinical hyperthyroidism, with a hazard ratio of 3.3, after adjustment of risk factors from stroke [74].

In another cohort study from Denmark, which analyzed over 47 000 subjects consulting their general practitioner, Selmer et al. found that subclinical hyperthyroidism was not associated with stroke [75]. However, when considered the combined end point of major adverse cardiovascular events, which included cardiovascu-

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Age</th>
<th>Female, n (%)</th>
<th>Events, n (%)</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atrial fibrillation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selmer C [90]</td>
<td>6276</td>
<td>60.6 ± 19.4</td>
<td>4784 (76.2 %)</td>
<td>435 (6.9 %)</td>
<td>5.5 years</td>
</tr>
<tr>
<td>Cappola AR [71]</td>
<td>47</td>
<td>73.9 ± 6.8</td>
<td>32 (68.1 %)</td>
<td>4 (8.5 %)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>43</td>
<td>N/A</td>
<td>N/A</td>
<td>22 (51.2 %)</td>
<td></td>
</tr>
<tr>
<td>Auer JA [48]</td>
<td>613</td>
<td>67.9 ± 9.2</td>
<td>N/A</td>
<td>78 (12.7 %)</td>
<td></td>
</tr>
<tr>
<td>Rosario PW [59]</td>
<td>90</td>
<td>74 (65–82)</td>
<td>90 (100.0 %)</td>
<td>4 (4.4 %)</td>
<td></td>
</tr>
<tr>
<td>Gammage MD [49]</td>
<td>126</td>
<td>N/A</td>
<td>72 (57.1 %)</td>
<td>12 (9.5 %)</td>
<td></td>
</tr>
<tr>
<td>Goichot B [91]</td>
<td>86</td>
<td>N/A</td>
<td>N/A</td>
<td>10 (11.6 %)</td>
<td></td>
</tr>
<tr>
<td>Wollenweber FA [76]</td>
<td>19</td>
<td>75 (61–80)</td>
<td>10 (53.0 %)</td>
<td>7 (37.0 %)</td>
<td></td>
</tr>
<tr>
<td>Poola R [92]</td>
<td>116</td>
<td>55 (19–98)</td>
<td>88 (75.9 %)</td>
<td>8 (6.9 %)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>108</td>
<td>N/A</td>
<td>N/A</td>
<td>3 (2.8 %)</td>
<td></td>
</tr>
<tr>
<td>Nanchen D [80]</td>
<td>71</td>
<td>75.3 ± 3.1</td>
<td>54 (76.1 %)</td>
<td>7 (9.9 %)</td>
<td>3.2 years</td>
</tr>
<tr>
<td>Schultz M [74]</td>
<td>25</td>
<td>74.0 ± 10.0</td>
<td>20 (80.0 %)</td>
<td>1 (4.0 %)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>N/A</td>
<td>N/A</td>
<td>2 (8.3 %)</td>
<td>5.0 years</td>
</tr>
<tr>
<td>Duarte GC [93]</td>
<td>26</td>
<td>60–85**##</td>
<td>21 (80.8 %)</td>
<td>3 (11.5 %)</td>
<td></td>
</tr>
<tr>
<td>Drechsler C [73]</td>
<td>137</td>
<td>66.9 ± 7.9</td>
<td>74 (54.0 %)</td>
<td>16 (12.0 %)</td>
<td></td>
</tr>
<tr>
<td>Sawin CT [47]</td>
<td>248</td>
<td>N/A</td>
<td>156 (62.9 %)</td>
<td>36 (14.5 %)</td>
<td>10 years</td>
</tr>
<tr>
<td>Klein Hesselink * [94]</td>
<td>518</td>
<td>48.6 ± 13.4</td>
<td>387 (74.7 %)</td>
<td>35 (6.8 %)</td>
<td>8.7 years</td>
</tr>
<tr>
<td>Biondi B * [58]</td>
<td>20</td>
<td>N/A</td>
<td>18 (90.0 %)</td>
<td>1 (5.0 %)</td>
<td></td>
</tr>
<tr>
<td><strong>Stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drechsler C [73]</td>
<td>137</td>
<td>66.9 ± 7.9</td>
<td>74 (54.0 %)</td>
<td>7 (5.1 %)</td>
<td>4.0 years</td>
</tr>
<tr>
<td>Wollenweber FA [76]</td>
<td>19</td>
<td>75 (61–80)</td>
<td>10 (43.0 %)</td>
<td>1 (5.3 %)##</td>
<td></td>
</tr>
<tr>
<td>Schultz M [74]</td>
<td>25</td>
<td>74 ± 10</td>
<td>20 (80.0 %)</td>
<td>2 (8.0 %)##</td>
<td></td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>74 ± 10</td>
<td>20 (80.0 %)</td>
<td>4 (17.4 %)##</td>
<td>5.0 years</td>
</tr>
<tr>
<td>Selmer C [90]</td>
<td>6276</td>
<td>60.6 ± 19.4</td>
<td>4784 (76.0 %)</td>
<td>57 (0.9 %)##</td>
<td></td>
</tr>
<tr>
<td>Cappola AR [71]</td>
<td>47</td>
<td>73.9 ± 6.8</td>
<td>32 (68.1 %)</td>
<td>2 (4.3 %)##</td>
<td></td>
</tr>
<tr>
<td></td>
<td>31</td>
<td>N/A</td>
<td>N/A</td>
<td>4 (12.9 %)##</td>
<td>13 years</td>
</tr>
</tbody>
</table>

* Median and IQR; ** Median and range; **## Range; * Thyrotropin-suppressive therapy with l-thyroxine; $ Stroke recurrence; ¶ Prevalence; ¶¶ Incidence

---

Table 1  Studies that analyzed prevalence and incidence of atrial fibrillation and stroke in subjects with subclinical hyperthyroidism.
Subclinical hyperthyroidism is a common clinical problem, in particular in older subjects. However, few randomized controlled studies assessed cardiovascular endpoints after treatment of subclinical hyperthyroidism. Some authors demonstrated a reduction of heart rate, premature atrial and ventricular beats, but the clinical and prospective effects on cardiovascular outcome have not been studied and remain unclear. In addition, most of the studies had a small number of patients, without including a control arm.

The decision to treat subclinical hyperthyroidism is made on the clinical judge, which carefully examined age and comorbidities of the patient. When subclinical hyperthyroidism is diagnosed, experts suggested to repeat the measurement within 4 weeks for...
TSH < 0.1 mUI/l and after 3 months in subjects with TSH higher than 0.1 mUI/l and lower than 0.45 mUI/l [89]. Repeating measures allow discriminating transient (in particular transient thyroiditis) and persistent subclinical hyperthyroidism and avoid overtreatment.

The treatment in older subjects aimed to reduce the incidence of cardiovascular disease, mainly AF. Conversely, there are insufficient data for younger patients, even in case of TSH level < 0.1 mUI/l. The goal of therapy is to normalize TSH level and is based on the etiology of subclinical hyperthyroidism. Appropriate therapy could be radioactive iodine, in case of toxic multinodular goiter, antithyroid drug, in case younger subjects, and surgery, in those who has a concern for cancer.

Experts panel recommended against the routine treatment of subclinical hyperthyroidism in young and asymptomatic subjects with TSH > 0.1 mUI/l. Treatment should be considered in patients aged 65 or older, and in those with symptoms or comorbidities [89]. However, indications for the treatment are not supported by strong evidences because studies analyzing effect of the therapy are rather scanty. In addition, due to the small effect of subclinical hyperthyroidism on CVD and on all-cause mortality, it has been calculated that in order to achieve a power of 80%, sample sizes of the studies would need to be extremely wide in younger age (>12,000 patients) and more than 400 when considering only subjects >70 years [85].

Conflict of Interest

The authors declare that they have no conflict of interest.

References


[31] Das C, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Oksoyene OE. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (Oxf) 2012; 77: 146–151

[32] Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: A prospective study. Clin Endocrinol (Oxf) 2010; 72: 685–688


[40] Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes 2010; 17: 408–413

[41] Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hyperthyroidism. Thyroid 2000; 10: 665–679


[59] Rosario PW, Carvalho M, Calcolari MR. Symptoms of thyrotoxicosis, bone metabolism and occult atrial fibrillation in older women with mild endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 2016; 85: 132–136


[83] Asvold BO, Bjørn T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf) 2012; 77: 911–917


[89] Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228–238


